Patients are randomized in a 1:1 ratio ( 7-21days post-transplantation ) to receive everolimus ( trough levels 3-8ng / mL ) with reduced tacrolimus ( trough levels < 5ng/mL ) , or standard tacrolimus ( trough levels 6-10ng / mL ) after entering a run-in period ( 3-5days post-transplantation ) .